HK1042095A1 - 新型β-酰氨基-和β-氨磺酰羧酸衍生物，它們的製備和作為內皮縮血管肽受體拮抗物的應用 - Google Patents

新型β-酰氨基-和β-氨磺酰羧酸衍生物，它們的製備和作為內皮縮血管肽受體拮抗物的應用

Info

Publication number
HK1042095A1
HK1042095A1 HK02104116.9A HK02104116A HK1042095A1 HK 1042095 A1 HK1042095 A1 HK 1042095A1 HK 02104116 A HK02104116 A HK 02104116A HK 1042095 A1 HK1042095 A1 HK 1042095A1
Authority
HK
Hong Kong
Prior art keywords
amide
preparation
new
carboxylic acid
acid derivatives
Prior art date
Application number
HK02104116.9A
Other languages
English (en)
Inventor
W‧安博格
R‧詹森
G‧凱特肖
H‧理查斯
E‧鮑曼
S‧赫根羅德
M‧拉沙克
L‧昂格爾
Original Assignee
巴斯福股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 巴斯福股份公司 filed Critical 巴斯福股份公司
Publication of HK1042095A1 publication Critical patent/HK1042095A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK02104116.9A 1998-12-18 2002-05-31 新型β-酰氨基-和β-氨磺酰羧酸衍生物，它們的製備和作為內皮縮血管肽受體拮抗物的應用 HK1042095A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19858779A DE19858779A1 (de) 1998-12-18 1998-12-18 Neue ß-Amido und ß-Sulfonamidocarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten
PCT/EP1999/009679 WO2000037450A1 (de) 1998-12-18 1999-12-09 NEUE β-AMIDO- UND β-SULFONAMIDOCARBONSÄUREDERIVATE, IHRE HERSTELLUNG UND VERWENDUNG ALS ENDOTHELIN-REZEPTORANTAGONISTEN

Publications (1)

Publication Number Publication Date
HK1042095A1 true HK1042095A1 (zh) 2002-08-02

Family

ID=7891778

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02104116.9A HK1042095A1 (zh) 1998-12-18 2002-05-31 新型β-酰氨基-和β-氨磺酰羧酸衍生物，它們的製備和作為內皮縮血管肽受體拮抗物的應用

Country Status (18)

Country Link
EP (1) EP1140867A1 (zh)
JP (1) JP2002533330A (zh)
KR (1) KR20010101279A (zh)
CN (1) CN1334806A (zh)
AR (1) AR023353A1 (zh)
AU (1) AU3036400A (zh)
BG (1) BG105618A (zh)
BR (1) BR9916331A (zh)
CA (1) CA2355251A1 (zh)
CZ (1) CZ20012186A3 (zh)
DE (1) DE19858779A1 (zh)
HK (1) HK1042095A1 (zh)
HU (1) HUP0201321A3 (zh)
IL (1) IL143451A0 (zh)
NO (1) NO20013000L (zh)
SK (1) SK8682001A3 (zh)
TR (1) TR200101780T2 (zh)
WO (1) WO2000037450A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE303804T1 (de) * 2000-11-17 2005-09-15 Warner Lambert Co Behandlung von sexueller funktionsstörung mit bombesin rezeptor antagonisten
US7790770B2 (en) 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
ES2462065T3 (es) * 2009-07-10 2014-05-22 Cadila Healthcare Limited Proceso mejorado para la preparación de Ambrisentán e intermedios novedosos de este

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8912700D0 (en) * 1989-06-02 1989-07-19 Shell Int Research Herbicidal compounds
DE4329911A1 (de) * 1993-09-04 1995-03-09 Basf Ag Substituierte Milchsäurederivate mit einem N-organischen Rest in beta-Position
CN1247533A (zh) * 1996-12-18 2000-03-15 Basf公司 杂环羧酸衍生物,它们的制备方法和它们作为内皮素(endothelin)受体拮抗剂的用途
DE19726146A1 (de) * 1997-06-19 1998-12-24 Basf Ag Neue ß-Amino und ß-Azidopcarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten

Also Published As

Publication number Publication date
JP2002533330A (ja) 2002-10-08
IL143451A0 (en) 2002-04-21
TR200101780T2 (tr) 2001-11-21
HUP0201321A2 (hu) 2002-12-28
AU3036400A (en) 2000-07-12
HUP0201321A3 (en) 2003-02-28
CN1334806A (zh) 2002-02-06
SK8682001A3 (en) 2002-08-06
CZ20012186A3 (cs) 2002-07-17
WO2000037450A1 (de) 2000-06-29
DE19858779A1 (de) 2000-06-21
BG105618A (en) 2002-01-31
AR023353A1 (es) 2002-09-04
KR20010101279A (ko) 2001-11-14
CA2355251A1 (en) 2000-06-29
NO20013000L (no) 2001-08-15
EP1140867A1 (de) 2001-10-10
NO20013000D0 (no) 2001-06-15
BR9916331A (pt) 2001-09-11

Similar Documents

Publication Publication Date Title
HUP0202202A3 (en) Benzoxepino [2,3-b]pyridine derivatives and analogues as chemokine receptor antagonists and the use thereof
AU2001269876A1 (en) Heteroarylalkanoic acids as integrin receptor antagonists
IL152700A0 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinc receptor antagonists
HK1030939A1 (en) Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
HRP20000002B1 (en) Azetidinylpropylpiperidine derivatives, intermediates and use as tachykinin antagonists
HUP0003484A3 (en) Pyrrolidine-3-crboxylic acid derivatives and their use as endothelin antagonists
IL135347A0 (en) New carboxylic acid derivatives, carrying amido side-chains; production and use as endothelin receptor antagonists
IL145051A0 (en) 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy) -2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists
HK1045684A1 (en) Biphenyl derivatives as antagonists of the neurokinine-1 receptor.
AU5659498A (en) Heterocyclic carboxylic acid derivatives, their preparation ans use as endothelin receptor antagonists
ZA985277B (en) Novel ß-amino and ß-azido carboxylic and acid derivatives, their preparation and use as endothelin receptor antagonists.
NZ315846A (en) Endothelin receptor antagonists, in particular, substituted pyrazol-4-yl-substituted-prop-2-enoic acid derivatives
AUPQ570100A0 (en) Beta-alanine derivatives and their use as receptor antagonists
HK1042095A1 (zh) 新型β-酰氨基-和β-氨磺酰羧酸衍生物，它們的製備和作為內皮縮血管肽受體拮抗物的應用
HK1049151A1 (zh) 四氫化苯並吲衍生物、其製備方法和用作5-ht7受體拮抗劑的用途
ZA9810425B (en) Novel heterocyclically substituted Ó-hydroxycarboxylic acid derivatives, their preparation and use as endothelin receptor antagonists.
EP1169042A4 (en) DIBENZO-AZEPINE DERIVATIVES AS ANTAGONISTS OF THE ALPHA V INTEGRIN RECEPTOR
IL137038A0 (en) 5-substituted pyrimidine-2-yloxy carboxylic acid derivatives, the production of the same and their utilization as endothelin antagonists
ZA991738B (en) Novel unsymmetrically substituted carboxylic acid derivatives, their preparation and use as mixed et /et receptor antagonists.
IL146800A0 (en) Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their preparation and use as endothelin receptor antagonists
HUP0102531A3 (en) Carboxy substituted carboxamide derivatives and their use as tachykinin receptor antagonists
ZA9711305B (en) Heterocyclic carboxylic acid derivatives their preparation and use as endothelin receptor antagonists
ZA988053B (en) Novel carboxylic acid derivatives, their preparation and use as mixed ETA/ETB receptor antagonists.
IL147666A0 (en) Novel carboxylic acid derivatives with 5, 6 substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists